Decor Pharmaceuticals Private Limited
Founded in 2019 and headquartered in Uttar Pradesh, India.
2019 | Lucknow, Uttar Pradesh (India) | Active
Decor Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 0.10 M
- Company Age 6 Year, 20 Days
- Last Filing with ROC 31 Mar 2023
- Revenue Growth -1.16%
- Profit Growth -124.34%
- Ebitda -134.70%
- Net Worth -182.34%
- Total Assets 21.07%
About Decor Pharmaceuticals
Decor Pharmaceuticals Private Limited (DPPL) is a Private Limited Indian Non-Government Company incorporated in India on 06 February 2019 (Six years 20 days old ). Its registered office is in Lucknow, Uttar Pradesh, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Suresh Dixit and Umesh Chandra serve as directors at the Company.
Company Details
- Location
Lucknow, Uttar Pradesh, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U74999UP2019PTC113298
- Company No.
113298
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
06 Feb 2019
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Kanpur
Industry
Pharma
Who are the key members and board of directors at Decor Pharmaceuticals?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Suresh Dixit  | Director | 06-Feb-2019 | Current |
| Umesh Chandra | Director | 06-Feb-2019 | Current |
Financial Performance of Decor Pharmaceuticals.
Decor Pharmaceuticals Private Limited, for the financial year ended 2023, experienced Minor drop in revenue, with a 1.16% decrease. The company also saw a substantial fall in profitability, with a 124.34% decrease in profit. The company's net worth observed a substantial decline by a decrease of 182.34%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Decor Pharmaceuticals?
In 2023, Decor Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Decor Pharmaceuticals?
Unlock and access historical data on people associated with Decor Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Decor Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Decor Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
